The effects of recombinant human insulin-like growth factor-I/Insulin-like growth factor binding protein-3 administration on body composition and physical fitness in recreational athletes
The effects of recombinant human insulin-like growth factor-I/Insulin-like growth factor binding protein-3 administration on body composition and physical fitness in recreational athletes
Context:
Insulin-like growth factor-I (IGF-I) is thought to mediate many of the anabolic actions of growth hormone (GH) and there are anecdotal reports that IGF-I is misused by elite athletes. There is no published evidence regarding the effects of IGF-I administration on athletic performance.
Objective:
To investigate the effects of IGF-I administration on body composition and physical fitness in recreational athletes.
Design and Setting:
Randomised, double-blind, placebo-controlled rhIGF-I/rhIGFBP-3 administration study at Southampton General Hospital, UK.
Participants:
56 recreational athletes (30 men, 26 women)
Intervention:
Participants were randomly assigned to receive placebo, low dose rhIGF-I/rhIGFBP-3 (30 mg/day) or high dose rhIGF-I/rhIGFBP-3 (60 mg/day) for 28 days. Body composition (assessed by Dual Energy X-ray Absorptiometry) and cardiorespiratory fitness (assessed by incremental treadmill test), were measured before and immediately after treatment. Within-individual changes after treatment were analysed using paired t-tests.
Results:
There were no significant changes in body fat mass or lean body mass in women or men after administration of rhIGF-I/rhIGFBP-3 complex. There was a significant increase in maximal oxygen consumption (VO2 max) after treatment. When women and men and low and high dose treatment groups were combined, mean VO2 max increased by approximately 7% (P = 0.001). No significant change in VO2 max was observed in the placebo group.
Conclusions:
rhIGF-I/rhIGFBP-3 administration for 28 days improves aerobic performance in recreational athletes but there are no effects on body composition.
3126-3131
Guha, Nishan
38212040-a65e-4874-a60a-21f0ae3bdf09
Nevitt, Simon P.
c3b28987-b9cb-4c9a-96d8-dd543bbe482c
Francis, Michael
93112f9d-8b2b-454b-ab6f-7f0d286f09e0
Woodland, John A.
bb644fb2-0899-427a-af47-102d1603923a
Bohning, Dankmar
1df635d4-e3dc-44d0-b61d-5fd11f6434e1
Sonksen, Peter H.
b3cf05ef-65c2-4e9b-8d95-b7c3aaf532cd
Holt, R.I.G.
d54202e1-fcf6-4a17-a320-9f32d7024393
1 August 2015
Guha, Nishan
38212040-a65e-4874-a60a-21f0ae3bdf09
Nevitt, Simon P.
c3b28987-b9cb-4c9a-96d8-dd543bbe482c
Francis, Michael
93112f9d-8b2b-454b-ab6f-7f0d286f09e0
Woodland, John A.
bb644fb2-0899-427a-af47-102d1603923a
Bohning, Dankmar
1df635d4-e3dc-44d0-b61d-5fd11f6434e1
Sonksen, Peter H.
b3cf05ef-65c2-4e9b-8d95-b7c3aaf532cd
Holt, R.I.G.
d54202e1-fcf6-4a17-a320-9f32d7024393
Guha, Nishan, Nevitt, Simon P., Francis, Michael, Woodland, John A., Bohning, Dankmar, Sonksen, Peter H. and Holt, R.I.G.
(2015)
The effects of recombinant human insulin-like growth factor-I/Insulin-like growth factor binding protein-3 administration on body composition and physical fitness in recreational athletes.
Journal of Clinical Endocrinology & Metabolism, 100 (8), .
(doi:10.1210/jc.2015-1996).
Abstract
Context:
Insulin-like growth factor-I (IGF-I) is thought to mediate many of the anabolic actions of growth hormone (GH) and there are anecdotal reports that IGF-I is misused by elite athletes. There is no published evidence regarding the effects of IGF-I administration on athletic performance.
Objective:
To investigate the effects of IGF-I administration on body composition and physical fitness in recreational athletes.
Design and Setting:
Randomised, double-blind, placebo-controlled rhIGF-I/rhIGFBP-3 administration study at Southampton General Hospital, UK.
Participants:
56 recreational athletes (30 men, 26 women)
Intervention:
Participants were randomly assigned to receive placebo, low dose rhIGF-I/rhIGFBP-3 (30 mg/day) or high dose rhIGF-I/rhIGFBP-3 (60 mg/day) for 28 days. Body composition (assessed by Dual Energy X-ray Absorptiometry) and cardiorespiratory fitness (assessed by incremental treadmill test), were measured before and immediately after treatment. Within-individual changes after treatment were analysed using paired t-tests.
Results:
There were no significant changes in body fat mass or lean body mass in women or men after administration of rhIGF-I/rhIGFBP-3 complex. There was a significant increase in maximal oxygen consumption (VO2 max) after treatment. When women and men and low and high dose treatment groups were combined, mean VO2 max increased by approximately 7% (P = 0.001). No significant change in VO2 max was observed in the placebo group.
Conclusions:
rhIGF-I/rhIGFBP-3 administration for 28 days improves aerobic performance in recreational athletes but there are no effects on body composition.
Text
EarlyReleaseVersionJune2015.pdf
- Other
More information
Accepted/In Press date: 1 June 2015
e-pub ahead of print date: 5 June 2015
Published date: 1 August 2015
Organisations:
Faculty of Medicine
Identifiers
Local EPrints ID: 377918
URI: http://eprints.soton.ac.uk/id/eprint/377918
ISSN: 0021-972X
PURE UUID: 640d4b6c-b861-48f8-aee0-a3d051e518b3
Catalogue record
Date deposited: 24 Jun 2015 13:21
Last modified: 15 Mar 2024 03:39
Export record
Altmetrics
Contributors
Author:
Nishan Guha
Author:
Simon P. Nevitt
Author:
Michael Francis
Author:
John A. Woodland
Author:
Peter H. Sonksen
Download statistics
Downloads from ePrints over the past year. Other digital versions may also be available to download e.g. from the publisher's website.
View more statistics